专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2008103947A3 ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH CLEC-6 审中-公开
标题翻译：通过CLEC-6激活人类抗原呈递细胞
公开(公告)号：WO2008103947A3
公开(公告)日：2008-11-27
申请号：PCT/US2008054785
申请日：2008-02-22
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
发明人： BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
IPC分类号： C07K17/14
CPC分类号： C07K16/2851 , C07K2317/56 , C07K2317/74 , C07K2317/75
摘要： The present invention includes compositions and methods for using novel anti-CLEC-6 antibodies and fragments thereof for modulating the activity of immune cells.
摘要翻译：本发明包括使用新型抗CLEC-6抗体及其片段来调节免疫细胞活性的组合物和方法。

12. 发明申请

WO2011091319A3 DENDRITIC CELL VACCINES 审中-公开
标题翻译： DENDRITIC细胞疫苗
公开(公告)号：WO2011091319A3
公开(公告)日：2011-11-17
申请号：PCT/US2011022147
申请日：2011-01-21
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , MONTES MONICA , PALUCKA ANNA KAROLINA , SLOAN LOUIS M , LEVY YVES , AGENCE NATIONALE DE RECH S SUR LE SIDA ET LES HEPATITIS VIRALES
发明人： BANCHEREAU JACQUES F , MONTES MONICA , PALUCKA ANNA KAROLINA , SLOAN LOUIS M , LEVY YVES
IPC分类号： A61K39/12 , A61K31/18 , A61K38/04 , A61K38/16 , A61K39/21 , A61P31/18 , C12N5/0784
CPC分类号： C12N5/0639 , A61K39/12 , A61K39/21 , A61K2039/5154 , A61K2039/545 , A61K2039/6018 , C07K14/005 , C12N2501/052 , C12N2501/22 , C12N2501/24 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-a), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).
摘要翻译：本文公开了预防和治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。更具体地，本发明公开了一种通过用粒细胞巨噬细胞集落刺激因子（GM-CSF）和干扰素α2b（IFN-α）培养患者的单核细胞衍生的自体树突状细胞（DC）疫苗产品， 5种Gag，Nef和Pol HIV抗原的脂肽，以及任选地用脂多糖（LPS）活化DC。

13. 发明申请

WO2010104749A8 ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES 审中-公开
标题翻译：抗原呈递细胞靶向的癌症疫苗
公开(公告)号：WO2010104749A8
公开(公告)日：2011-09-15
申请号：PCT/US2010026275
申请日：2010-03-04
申请人： BAYLOR RES INST , ZURAWSKI GERALD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , MONTES MONICA , KLUCAR PETER , AKAGAWA KEIKO
发明人： ZURAWSKI GERALD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , MONTES MONICA , KLUCAR PETER , AKAGAWA KEIKO
IPC分类号： C07K19/00 , A61K39/395 , A61P35/00 , C07K16/30 , C12N15/62 , C12N15/63
CPC分类号： A61K39/0011 , A61K2039/6056 , C07K14/435 , C07K16/2878 , C07K2319/00 , C07K2319/33 , C07K2319/91
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
摘要翻译：本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

14. 发明申请

WO2008097866A3 VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED AN ANTIGEN-PRESENTING CELLS 审中-公开
标题翻译：基于抗DC抗原表达抗原呈递细胞的疫苗
公开(公告)号：WO2008097866A3
公开(公告)日：2008-12-24
申请号：PCT/US2008052850
申请日：2008-02-01
申请人： BAYLOR RES INST , ZURAWSKI GERALD , BANCHEREAU JACQUES F
发明人： ZURAWSKI GERALD , BANCHEREAU JACQUES F
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/2851 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/6897 , A61K47/6901 , A61K2039/505 , A61K2039/6056 , B82Y5/00 , C12N5/0639 , C12N2760/16134
摘要： The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
摘要翻译：本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递，与抗体 - 抗原复合物接触。

15. 发明申请

WO2008097870A2 AGENTS THAT ENGAGE ANTIGEN - PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC- ASGPR) 审中-公开
标题翻译：携带抗原的细胞 - 通过细胞核心蛋白质受体（DC-ASGPR）提供细胞
公开(公告)号：WO2008097870A2
公开(公告)日：2008-08-14
申请号：PCT/US2008052865
申请日：2008-02-02
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
发明人： BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
IPC分类号： C12N5/06 , A61K35/12 , A61K39/00 , A61K39/395 , A61P37/00 , C07K16/18 , C12N9/00
CPC分类号： A61K39/145 , A61K47/6849 , A61K51/1027 , A61K2039/5154 , C07K14/005 , C07K14/195 , C07K14/37 , C07K14/405 , C07K14/435 , C07K16/28 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/74 , C07K2317/75 , C07K2317/92 , C12N5/0639 , C12N7/00 , C12N2760/16122 , C12N2760/16134
摘要： The present invention includes compositions and methods for making and using anti DC- ASGPR antibodies that can, e.g., activate DCs and other cells.
摘要翻译：本发明包括用于制备和使用可以例如激活DC和其他细胞的抗DC-ASGPR抗体的组合物和方法。

16. 发明申请

WO2004050855A3 RAPID ONE-STEP METHOD FOR GENERATION OF ANTIGEN LOADED DENDRITIC CELL VACCINE FROM PRECURSORS 审中-公开
标题翻译：用于从前体产生抗原负载的细胞真菌的快速一步法
公开(公告)号：WO2004050855A3
公开(公告)日：2005-02-03
申请号：PCT/US0338553
申请日：2003-12-04
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , PALUCKA ANNA K
发明人： BANCHEREAU JACQUES F , PALUCKA ANNA K
IPC分类号： A61K39/00 , C12N5/02 , C12N5/0784 , A01N63/00 , A61K45/00 , A61K47/00 , C12N5/00 , C12N5/06
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/5154 , C12N5/0639 , C12N2501/22 , C12N2501/25
摘要： A one-step method for producing antigen loaded antigen-presenting cells from monocytes ex vivo has been found which comprises contacting the monocytes with a composition comprising an activator such as TNF alpha preferably in combination with at least one growth factor such as GM-CSF and at least one soluble or particulate antigen. According to the methods of the present invention, antigen-loaded dendritic cell vaccines can be generated within as little as three (3) days. In another method of the present invention, antigen loaded antigen-presenting cells are produced from monocytes ex vivo by contacting the monocytes with TNF alpha and granulocyte-macrophage colony stimulating factor at one time point to form antigen-presenting cells and then contacting antigenpresenting cells with soluble or particulate antigenic material at a second time point to form antigen loaded antigen-presenting cells, wherein the antigen loaded antigen-presenting cells are produced in less than four days. The present invention also includes a vaccine which comprises monocyte-derived antigen loaded antigen-presenting cells, wherein the antigenpresenting cells are composed of two or more subsets selected from the group consisting of Langerhans cells with surface markers (CD 1 a+ CD207+); interstitial dendritic cells with surface markers (CD 1a+ CD207-); double negative dendritic cells with surface markers 20 (CD 1 a-CD 14-); and dendritic cells with surface markers (CD 14+ CD 1 a- CD209+).
摘要翻译：已经发现从体外从单核细胞产生抗原负载抗原呈递细胞的一步法包括使单核细胞与包含活化剂如TNFα的组合物接触，优选与至少一种生长因子如GM-CSF和至少一种可溶或微粒抗原。根据本发明的方法，可以在短短三（3）天内产生抗原负载的树突状细胞疫苗。在本发明的另一种方法中，抗原呈递细胞由单核细胞通过单核细胞与TNFα和粒细胞 - 巨噬细胞集落刺激因子在一个时间点接触形成抗原呈递细胞，然后将抗原呈递细胞与可溶性或微粒状抗原物质，以形成抗原负载的抗原呈递细胞，其中抗原呈递细胞在不到四天内产生。本发明还包括一种疫苗，其包含单核细胞衍生的抗原负载抗原呈递细胞，其中所述抗原呈递细胞由两个或更多个选自具有表面标记的朗格汉斯细胞（CD1a + CD207 +）的子集组成; 具有表面标志物的间质树突状细胞（CD 1a + CD207-）; 具有表面标记20的双负性树突状细胞（CD 1 a-CD 14-）; 和具有表面标志物的树突状细胞（CD14 + CD11a-CD209 +）。

17. 发明申请

WO0129192A3 USE OF ALLOGENEIC CELL LINES TO LOAD ANTIGEN-PRESENTING CELLS TO ELICIT OR ELIMINATE IMMUNE RESPONSES 审中-公开
标题翻译：使用同种异体细胞系负载抗原呈递细胞以免疫或免疫免疫应答
公开(公告)号：WO0129192A3
公开(公告)日：2002-01-17
申请号：PCT/US0028670
申请日：2000-10-16
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , BERARD FREDERIC , BLANCO PATRICK , NEIDHART BERARD EVE MARIE , NOURI SHIRAZI MAHYAR , PALUCKA ANNA KAROLINA
发明人： BANCHEREAU JACQUES F , BERARD FREDERIC , BLANCO PATRICK , NEIDHART-BERARD EVE-MARIE , NOURI-SHIRAZI MAHYAR , PALUCKA ANNA KAROLINA
IPC分类号： A61K35/12 , A61K39/00 , A61P35/00 , C12N5/0784 , C12N5/08
CPC分类号： C12N5/0639 , A61K39/0008 , A61K39/001 , A61K39/0011 , A61K2035/122 , A61K2039/5152 , A61K2039/5154 , A61K2039/5158 , A61K2039/57 , C12N5/064
摘要： Novel antigen-presenting cells, including but not limited to dendritic cells (DC), that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells are useful to induce both prophylactic immune responses and therapeutic immune responses in humans. In particular, such loaded antigen-presenting cells are useful in the management of cancer and infectious diseases. Alternatively, the loaded antigen-presenting cells can be used to eliminate undesired immune responses such as autoimmune responses and graft versus host disease or host versus graft reaction, i.e., graft rejection in organ and bone marrow transplantation. Antigen-presenting cells useful in the present invention include but are not limited to dendritic cells at various differentiation stages (precursors, immature dendritic cells and mature dendritic cells), dendritic cells derived from blood precursors including but not limited to monocytes, dendritic cells derived from CD34-hematopoetic progenitor cells, subsets of dentritic cells such as Langerhans cells, interstitial DCs and lymphoid DCs. The antigen-presenting cells and the precursors of cytotoxic cells are derived from healthy volunteers or from tumor-bearing patients. Antigen-loaded dendritic cells prepared as described here can also prime naïve T cells to differentiate into effector cells able to recognize multiple and/or shared tumor antigens that are expressed either on the tumor cells that are used to load the dentritic cells and/or on other tumor cells. The cytotoxic T cells generated by exposure to antigen-loaded dendritic cells prepared as described here can also be used in adoptive therapy. This induction of responses against multiple antigens shared between different cells, for instance tumor cells, as described here is important as it leads to broad immune responses. In the present invention, the T cells that are exposed to dendritic cells loaded with killed cells can be tolerized against the antigen(s) expressed on the killed cells. That can be achieved by manipulation of loaded dentritic cells that allows presentation of the antigen but inhibits the expression of co-stimulatory molecules.
摘要翻译：描述了载有来自死亡或死亡细胞（包括同种异体细胞系）的抗原的新型抗原呈递细胞，包括但不限于树突细胞（DC），以及制备这种抗原呈递细胞的方法。这些负载的抗原呈递细胞可用于诱导人类的预防性免疫应答和治疗性免疫应答。特别地，这种负载的抗原呈递细胞可用于治疗癌症和感染性疾病。或者，加载的抗原呈递细胞可用于消除不期望的免疫应答，例如自身免疫应答和移植物抗宿主病或宿主与移植物反应，即在器官和骨髓移植中的移植排斥反应。可用于本发明的抗原呈递细胞包括但不限于在各种分化阶段的树突状细胞（前体，未成熟树突细胞和成熟树突状细胞），衍生自血液前体的树突状细胞，包括但不限于单核细胞，衍生自 CD34-造血祖细胞，诸如朗格汉斯细胞，间质性DCs和淋巴样DCs的树突状细胞亚群。抗原呈递细胞和细胞毒性细胞的前体衍生自健康志愿者或来自肿瘤的患者。如本文所述制备的抗原负载的树突状细胞也可以使初始的T细胞分化成能够识别多次和/或共享肿瘤抗原的效应细胞，所述多个和/或共有的肿瘤抗原在用于装载树突细胞的肿瘤细胞上表达和/或在其他肿瘤细胞。通过暴露于如本文所述制备的抗原负载的树突状细胞产生的细胞毒性T细胞也可用于过继疗法。如本文所述，这种对不同细胞（例如肿瘤细胞）共有的多种抗原的反应诱导是重要的，因为它导致广泛的免疫应答。在本发明中，暴露于负载有杀死细胞的树突细胞的T细胞可以耐受在杀死的细胞上表达的抗原。这可以通过操作允许呈递抗原但抑制共刺激分子的表达的负载的树突状细胞来实现。

18. 发明申请

WO2011032161A3 VACCINES DIRECTED TO LANGERHANS CELLS 审中-公开
标题翻译：疫苗被导入朗格汉斯细胞
公开(公告)号：WO2011032161A3
公开(公告)日：2011-08-25
申请号：PCT/US2010048800
申请日：2010-09-14
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , ZURAWSKI SANDRA , ZURAWSKI GERARD , KLECHEVSKY EYNAV , OH SANGKON
发明人： BANCHEREAU JACQUES F , ZURAWSKI SANDRA , ZURAWSKI GERARD , KLECHEVSKY EYNAV , OH SANGKON
IPC分类号： A61K39/395 , A61K38/16 , A61K38/17 , A61P25/00 , A61P35/00
CPC分类号： C07K16/2896 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/505 , A61K2039/5154 , A61K2039/55561 , A61K2039/6056 , C07K14/005 , C07K14/4748 , C07K16/2851 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2740/16034 , C12N2760/16134
摘要： The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy- terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.
摘要翻译：本发明包括分离的抗Langerin疫苗，在分离的抗Langerin抗体的羧基末端制备和使用分离的抗Langerin抗体或其结合片段和一个或多个抗原肽的方法，其中当两个或更多个抗原肽存在时，肽被包含至少一个糖基化位点的一个或多个接头肽分开。本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。

19. 发明申请

WO2011066008A3 BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION 审中-公开
标题翻译：活动性血清MYCOBACTERIUM TUBCCOSOS感染的血液转录水平
公开(公告)号：WO2011066008A3
公开(公告)日：2011-07-21
申请号：PCT/US2010046042
申请日：2010-08-19
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , CHAUSSABEL DAMIEN , O'GARRA ANNE , BERRY MATTHEW , KON ONN MIN , MEDICAL RES COUNCIL ON BEHALF OF THE NAT INST FOR MEDICAL RES , IMP COLLEGE HEALTHCARE NHS TRUST
发明人： BANCHEREAU JACQUES F , CHAUSSABEL DAMIEN , O'GARRA ANNE , BERRY MATTHEW , KON ONN MIN
IPC分类号： C12Q1/68 , C12N15/31 , C12R1/32 , G01N33/15
CPC分类号： C12Q1/689 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
摘要： The present invention includes methods, systems and kits for distinguishing between active and latent Mycobacterium tuberculosis infection in a patient suspected of being infected with Mycobacterium tuberculosis, the method including the steps of obtaining a patient gene expression dataset from a patient suspected of being infected with Mycobacterium tuberculosis; sorting the patient gene expression dataset into one or more gene modules associated with Mycobacterium tuberculosis infection; and comparing the patient gene expression dataset for each of the one or more gene modules to a gene expression dataset from a non-patient; wherein an increase or decrease in the totality of gene expression in the patient gene expression dataset for the one or more gene modules is indicative of active Mycobacterium tuberculosis infection.
摘要翻译：本发明包括用于区分疑似感染结核分枝杆菌的患者中的活性和潜在结核分枝杆菌感染的方法，系统和试剂盒，所述方法包括以下步骤：从疑似感染分枝杆菌的患者获得患者基因表达数据集结核; 将患者基因表达数据集分类成与结核分枝杆菌感染相关的一个或多个基因模块; 以及将所述一个或多个基因模块中的每一个的患者基因表达数据集与来自非患者的基因表达数据集进行比较; 其中所述一个或多个基因模块的患者基因表达数据集中基因表达的总和的增加或减少指示活动性结核分枝杆菌感染。

20. 发明申请

WO2010104748A3 ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES 审中-公开
标题翻译：抗原呈递细胞靶向的反病毒疫苗
公开(公告)号：WO2010104748A3
公开(公告)日：2011-03-03
申请号：PCT/US2010026273
申请日：2010-03-04
申请人： BAYLOR RES INST , ZURAWSKI GERARD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , LEVY YVES , MONTES MONICA
发明人： ZURAWSKI GERARD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , LEVY YVES , MONTES MONICA
IPC分类号： C07K19/00 , A61K39/12 , A61K39/395 , C07K16/08 , C12N15/62 , C12N15/63
CPC分类号： A61K39/0011 , A61K2039/6056 , C07K14/435 , C07K16/2878 , C07K2319/00 , C07K2319/33 , C07K2319/91
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
摘要翻译：本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式